CHMP Favors Kaftrio to Treat Children in EU Starting at Age 6

CHMP Favors Kaftrio to Treat Children in EU Starting at Age 6

312036

CHMP Favors Kaftrio to Treat Children in EU Starting at Age 6

A branch of the European Medicines Agency (EMA) has recommended expanding Kaftrio (ivacaftor/tezacaftor/elexacaftor), in combination with Kalydeco (ivacaftor), to include children with cystic fibrosis (CF) as young as age 6 who have at least one F508del mutation. The recommendation, from the EMA’s Committee for Medicinal Products for Human Use (CHMP), now will be reviewed by the European Commission, which issues a final ruling. If approved, more than 1,500 children in Europe would become eligible for Kaftrio, according to…

You must be logged in to read/download the full post.